Seasonal Influenza Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Seasonal Influenza Market Size Likely To Evolve From 2025 Through 2034?

The seasonal influenza market has seen rapid expansion in recent years. It is projected to increase from $8.41 billion in 2024 to $9.85 billion in 2025, at a compound annual growth rate (CAGR) of 17.1%. This historical growth can be linked to the increasing occurrence of influenza, a growing older demographic, a rise in infectious and chronic diseases, the escalating burden of illnesses associated with influenza, and an increase in respiratory infections.

The seasonal influenza market size is projected to undergo significant expansion in the coming years. It is forecast to achieve a size of $18.39 billion by 2029, growing at a compound annual growth rate (CAGR) of 16.9%. This expansion during the forecast period can be attributed to an elevated demand for oral drug solutions, increased research and development initiatives, a rise in vaccination numbers, enhancements in healthcare infrastructure, and an escalating need for retail pharmacies. Prominent trends for the forecast period encompass advancements in treatment, technological progress, developments in vaccine technology, the integration of mRNA technology, and digital health solutions for monitoring and diagnosis.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which Drivers Are Shaping The Seasonal Influenza Industry’s Market Share?

A projected increase in respiratory infections is anticipated to drive the expansion of the seasonal influenza market in the future. These infections are defined as conditions resulting from viral or bacterial agents that impact the respiratory tract, encompassing areas such as the sinuses, throat, airways, or lungs. The rising incidence of respiratory infections stems from factors like air pollution, shifting climates, compromised immune systems, and the effortless spread of viruses in congested or inadequately ventilated environments. Seasonal influenza therapies contribute to preventing or mitigating the severity of respiratory infections through various mechanisms, predominantly by targeting the influenza virus and controlling symptoms that might progress into secondary infections. As an illustration, in October 2024, data from the UK Health Security Agency, a UK-based government body, revealed that instances of tuberculosis (TB)—a respiratory infection caused by the bacterium Mycobacterium tuberculosis—in England saw a 10.7% year-over-year increase in 2023, escalating from 4,380 cases in 2022 to 4,850 cases. Consequently, this upsurge in respiratory infections will fuel the growth of the seasonal influenza market.

What Are The Major Segments Identified In The Seasonal Influenza Market?

The seasonal influenzamarket covered in this report is segmented –

1) By Type: Influenza A Virus; Influenza B Virus; Influenza C Virus; Influenza D Virus

2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations

3) By Distribution Channel: Hospital; Government and institutional supply; Pharmacy; Online

4) By Treatment: Antiviral; Neuraminidase Inhibitors; Vaccination; Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1; Subtype H3N2; Other Subtypes

2) By Influenza B Virus: Lineage Victoria; Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus; Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

What Long-Term Trends Will Shape The Future Growth Of The Seasonal Influenza Industry?

Companies operating within the seasonal influenza market are concentrating on advancements in treatment, particularly combination vaccines, to boost immunity by targeting multiple viral strains, thereby enhancing effectiveness and reducing the necessity for frequent vaccinations. These combination vaccines provide protection against various diseases or strains with a single injection, thus decreasing the total number of shots required for immunization. For illustration, in October 2023, Moderna, Inc., a US-based biotechnology company, announced encouraging interim Phase 1/2 trial results for mRNA-1083, its investigational combination vaccine aimed at both influenza and COVID-19. Developed to improve compliance, streamline administration, and offer greater convenience for individuals and healthcare systems, mRNA-1083 is presently being evaluated for safety and immunogenicity in comparison to standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), alongside a comparison to the Spikevax booster.

Which Key Market Players Are Investing In Expansion And Innovation Of Seasonal Influenza Market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Seasonal Influenza Market?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Seasonal Influenza Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp

Browse Through More Reports Similar to the Global Seasonal Influenza Market 2025, By The Business Research Company

Influenza Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795